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ABSTRACT
The introduction of serum Prostate Specific Antigen (PSA) testing nearly 30 
years ago has been associated with a significant shift towards localized disease and 
decreased deaths due to prostate cancer. Recognition that PSA testing has caused 
over diagnosis and over treatment of prostate cancer has generated considerable 
controversy over its value, and has spurred efforts to identify prognostic biomarkers 
to distinguish patients who need treatment from those that can be observed. Recent 
studies show that cancer is heterogeneous and forms a hierarchy of tumor cell 
populations. We developed a method of identifying prostate cancer differentiation 
states related to androgen signaling using Boolean logic. Using gene expression data, 
we identified two markers, CD38 and ARG2, that group prostate cancer into three 
differentiation states. Cancers with CD38-, ARG2- expression patterns, corresponding 
to an undifferentiated state, had significantly lower 10-year recurrence-free 
survival compared to the most differentiated group (CD38+ARG2+). We carried out 
immunohistochemical (IHC) staining for these two markers in a single institution 
(Stanford; n = 234) and multi-institution (Canary; n = 1326) cohorts. IHC staining 
for CD38 and ARG2 in the Stanford cohort demonstrated that combined expression of 
CD38 and ARG2 was prognostic. In the Canary cohort, low CD38 protein expression 
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by IHC was significantly associated with recurrence-free survival (RFS), seminal 
vesicle invasion (SVI), extra-capsular extension (ECE) in univariable analysis. In 
multivariable analysis, ARG2 and CD38 IHC staining results were not independently 
associated with RFS, overall survival, or disease-specific survival after adjusting 
for other factors including SVI, ECE, Gleason score, pre-operative PSA, and surgical 
margins.
INTRODUCTION
Although screening and early detection of prostate 
cancer (PC) has been associated with a drop in prostate 
cancer specific mortality in the US population and in 
the European Randomized Study of Prostate Cancer 
(ERSPC), PSA testing leads to significant over-detection 
and over-treatment of localized disease [1, 2]. Because of 
morbidities arising from local therapies such as surgery or 
radiation therapy and lack of benefit in large randomized 
trials of PSA screening and surgery in the U.S., the 
U.S. Preventative Services Task Force had, for 5 years, 
recommended against PSA testing [3–5]. Recently this 
recommendation was revised in favor of discussing the 
risks and benefits of PSA testing after several criticisms 
of the US trials and a dramatic shift in management of 
low risk patients to Active Surveillance (AS) [6]. Since 
30–50% of men on AS will reclassify to higher volume 
or higher Gleason score after 5 years of surveillance [7], 
considerable effort has been devoted to identifying early 
those men at high risk for reclassification by developing 
prognostic biomarkers. We have focused on identifying and 
validating tissue-based immunohistochemical biomarkers 
of aggressiveness since they can be widely deployed in 
pathology suites and are relatively inexpensive [8].
Many prognostic biomarkers have been identified 
by association of their expression with adverse 
pathological and clinical features including failure after 
primary therapy. One of the cardinal features of cancer 
is dedifferentiation, often due to activation of programs 
active during tissue development [9]. Previously, we have 
used Boolean logic to discover differentiation programs 
modulated in bladder and colon cancer [10–12]. Although 
less is known about the developmental programs in the 
normal prostate, we applied Boolean logic to identify 
transcripts co-regulated with AR and its downstream 
target PSA that are differentially expressed in the luminal 
and basal compartments of the normal prostate acinus. 
We chose the AR signaling pathway since it is central to 
prostate development and function [13, 14].
Normal prostate tissue is comprised of exocrine 
glands embedded in the prostate stroma containing 
fibroblasts, variable numbers of inflammatory cells, and 
smooth muscle cells. Current evidence demonstrates 
that a subset of the basal cells proliferate and give rise 
to terminally differentiated luminal secretory cells, 
suggesting that there are stem-like cells in the basal 
layer [15–18]. The luminal cells express prostate specific 
antigen (PSA or KLK3), prostatic acid phosphatase (PAP), 
androgen receptor (AR), and keratins (K) 8 and 18, 
while the basal cells express K5 and K14 [19]. Although 
prostate tumors display a strong luminal phenotype, it 
is still unclear whether basal cells [20] or luminal cells 
[21] are the cell of origin for prostate cancer. Hierarchies 
within the luminal cell types are poorly understood. It 
has been proposed that graded level of PSA or AR may 
define different stages of differentiation within luminal 
compartment [22].
Based on observations in bladder, colon and 
myeloid cells, we hypothesized that prostate cancer 
cells may have a path of differentiation in which 
several genes are turned on at different stages of 
differentiation [10–12]. We therefore used Boolean 
logic to identify transcripts modulated between basal 
and epithelial cells. We identified two genes, CD38 
and ARG2 that appear to be associated with prostate 
cancer differentiation. We tested whether expression 
level of these transcripts was prognostic using prostate 
cancer gene expression datasets with associated long-
term follow-up. In addition, we tested whether protein 
expression, measured by IHC, could be used as a 
clinical biomarker of prognosis.
RESULTS
Identification of markers of differentiation in 
prostate cancer
We assembled a large prostate cancer mRNA dataset 
(Global-Prostate) for Boolean analysis as shown in Figure 1. 
The dataset included 459 prostate cancer samples, 
140 stroma samples from prostate tissue, 116 benign 
prostatic hyperplasia, 100 normal prostate tissues, 
49 prostatic intraepithelial neoplasia, 17 dysplasia, 
and 10 cell lines (Total 891 samples). To identify 
differentiation specific markers, we searched for 
Boolean expression patterns between PSA (KLK3) 
and other genes: “KLK3 low => X low” and its 
counterpart “X high => KLK3 high” (Figure 1A, 1B 
Supplementary Figure 1). The resulting gene list included 
57 transcripts (using s > 10, p < 0.01 threshold for the 
BooleanNet analysis). To filter this list, we assembled 
three independent publicly available prostate cancer 
datasets that were annotated for recurrence-free survival 
and tested whether the transcripts were correlated with 
recurrence after surgery [23–25]. We used Sboner-2010 
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as the discovery dataset that revealed 6 transcripts are 
associated with outcome. One transcript, AZGP1, is a 
known androgen regulated gene that we have shown 
previously is an independent predictor of outcome after 
surgery in the Canary TMA cohort [26]. These candidates 
were validated on Tayler-2010 and Gerald-2004 dataset 
where all 6 candidates were associated with outcome in 
at-least one of the dataset. We chose CD38 and ARG2 
Figure 1: Schematic of experimental design. A database of 891 samples (Global-Prostate) related to prostate cancer (n = 459), 
stroma (n = 140), benign prostatic hyperplasia (BPH, n = 116), normal prostate (n = 100), prostatic intraepithelial neoplasia (PIN, n = 
49), dysplasia (n = 17), and cell line (n = 10) was created for gene expression analysis. Boolean analysis was performed to identify simple 
logical patterns between high and low expression values of two genes. A list of 57 candidate genes satisfied “KLK3 (PSA) low => X 
low” Boolean patterns. These candidates were filtered using high dynamic range and association with outcome using the Sboner-2010 (n 
= 281) as the discovery dataset resulting six candidates. Candidates were evaluated for their association with disease-free survival using 
two independent validation datasets (Gerald-2004 n = 78, Taylor-2010 n = 140, Total n = 218). All six candidates were significantly (p 
< 0.05) associated with disease-free survival in at least one dataset (Gerald and Taylor). Two of them (CD38 and ARG2) were chosen for 
immunohistochemical staining-based validation because of availability of good antibodies and their significant (p < 0.05) association with 
disease-free survival in all three datasets.
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because they were associated with outcome in all three 
datasets and IHC reagents were available that performed 
well on fixed and paraffin embedded tissues.
CD38 and ARG2 have a robust Boolean 
implication relationship with KLK3 and AR as shown 
in Figure 2. When ARG2 was compared with KLK3 in 
the Global-Prostate dataset, we observed that the ARG2 
high and KLK3 low quadrant was significantly sparse 
(FDR < 1e-4), thereby satisfying criteria for a Boolean 
implication relationship. CD38 showed a similar Boolean 
relationship with KLK3 and with ARG2. A detailed 
investigation of the gene expression relationship 
between CD38 and ARG2 demonstrated Boolean 
relationship “CD38 high => ARG2 high” (Figure 2A) 
and three possible groupings of prostate cancer cases: 
CD38+ARG2+, CD38-ARG2+, and CD38-ARG2- 
(Figure 2B). We investigated the relationship between 
AR, CD38 and ARG2. Since the AR mRNA expression 
range was small, we relaxed the threshold (use t-0.5 as 
the threshold) and perform analysis without ignoring 
the noise zone as shown in Figure 2C. This analysis 
revealed a “CD38 high => AR high” and “ARG2 high 
=> AR high” Boolean relationship. Both AR and PSA 
(KLK3) were expressed at low levels in basal cells 
and progressively expressed at high levels as cells are 
differentiated. Together with this differentiation related 
expression patterns of AR and KLK3 and the Boolean 
relationship between CD38, ARG2, AR and KLK3, the 
best possible scenario for ARG2 and CD38 expression 
pattern can be derived as shown in Figure 2D. ARG2 
expression is hypothesized to turn on earlier compared 
to CD38 expression along the path of differentiation 
which is consistent with “CD38 high => ARG2 high”. 
From this analysis, we hypothesized that differentiation 
proceeds from CD38-ARG2- (least differentiated), to 
CD38-ARG2+ (moderately differentiated) and finally 
CD38+ARG2+ (most differentiated) (Figure 2D).
As expected, Boolean analysis on these three 
datasets confirmed the existence of three differentiation 
states: CD38+ARG2+, CD38-ARG2+, and CD38-ARG2-. 
Cases were grouped using these criteria, and 10-year 
recurrence-free survival was compared each of the 3 
groups. In the Taylor et al. dataset, Kaplan–Meier analysis 
demonstrated that recurrence after surgery occurred 
in the expected order with CD38-ARG2- showing the 
highest risk of recurrence, CD38-ARG2+ intermediate 
risk and CD38+ARG2+ showing the lowest rates of 
recurrence (Figure 3A, p < 0.001). We observed similar 
results in Sboner-2010 dataset (Figure 3B, p < 0.001) and 
Gerald-2004 dataset (Figure 3C, p < 0.01).
Association of CD38 and ARG2 protein 
expression with clinical and pathological features
Expression of CD38 and ARG2 proteins was tested 
by IHC and associated with patient outcome using 2 tissue 
microarray sets representing independent patient datasets. 
Scoring strategies for CD38 and ARG2 are summarized 
in Figure 4A, 4B, Supplementary Figures 2, 3, and 4. In 
the Stanford-TMA dataset, we segregated cases into two 
groups of patients: CD38-ARG2- and CD38+/ARG2+ as 
described in the method section. Neither CD38 nor ARG2 
was significantly associated with outcome when analyzed 
individually (Supplementary Figure 5A and 5B). When 
the biomarkers were used to create a combined score, we 
observed that the rate of 10-year RFS for CD38+/ARG2+ 
group was significantly higher compared to CD38-ARG2- 
group (Figure 4C, Supplementary Figure 5C, p < 0.05). 
However, this association was not significantly associated 
with RFS after adjusting for other clinical factors in the 
model such as grade, age and stage. 
Since the Stanford-TMA cohort included 234 
patients, it was possible that this set was underpowered 
to test whether CD38 and ARG2 protein expression was 
independent of clinical and pathological variables. We 
therefore assessed expression of ARG2 and CD38 in 
the context of clinical and pathological features using 
the Canary-TMA which includes over 1300 cases from 
7 institutions. In this cohort, decreased CD38 protein 
expression by IHC was associated with decreased 
recurrence free survival in Kaplan–Meier analysis 
(Figure 4D, Supplementary Figure 6A, p < 0.05, Log-
rank test). In addition, negative/weak CD38 expression 
was significantly associated with adverse pathological 
features including seminal vesicle invasion (Table 1, 
SVI, P = 0.01, Fisher’s exact test) and extracapsular 
extension (Table 1, ECE, P = 0.02, Fisher’s exact test). 
CD38 expression did not correlate with age, pre-operative 
serum PSA levels, positive surgical margins (PSM) 
or Gleason score (GS), although there was a trend for 
lower expression associated with higher Gleason score 
(Supplementary Table 2). Univariable Cox proportional 
hazard model analysis showed that negative/weak CD38 
staining by IHC was significantly associated with worse 
RFS (Table 2, p = 0.01), as were PSM, SVI, ECE, higher 
GS, and higher pre-operative PSA. However, CD38 IHC 
was not significantly associated with RFS, OS, or DSS 
after adjusting for other clinical factors in the multivariate 
analysis (Supplementary Table 3). In the Canary-
TMA cohort, ARG2 protein level neither alone nor in 
combination with CD38 was associated with RFS, DSS, 
OS or any of the clinical and pathological variables on 
univariable and multivariable analysis (Supplementary 
Figure 6B).
DISCUSSION
We used Boolean logic to identify genes whose 
expression correlates with the androgen signaling axis, 
a pathway activated in terminally differentiated prostate 
luminal cells. We identified loss of expression of CD38 
protein as a prognostic biomarker that correlates with 
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several features of aggressive prostate cancer including 
advanced stage (T3 including both SVI and ECE) and 
RFS. Our data clearly demonstrate that CD38 and ARG2 
identify three different differentiation states in prostate 
cancer. There is a robust Boolean pattern that relates the 
expression of CD38 and ARG2; namely, when CD38 
expression levels are high, ARG2 expression levels are 
also high. The findings in the current study, coupled with 
our work in bladder and colon cancer and myeloid cell 
development [10–12], strongly suggest that application 
of Boolean analysis to large gene expression datasets 
can provide biological insights and define new clinically 
relevant prognostic biomarkers.
There have been a few relatively small studies of 
CD38 in the normal and malignant prostate. A graded 
decrease in CD38 protein expression has been observed 
in 23 prostate samples comparing normal prostate glands 
distant from cancer with normal glands adjacent to cancer, 
Figure 2: Relationship between KLK3, AR, ARG2 and CD38. Scatter plots showing relationships between KLK3 (PSA), ARG2 
and CD38 in the Global-Prostate database containing 891 samples. Red lines indicate StepMiner threshold and light blue lines indicate 
noise margin around the threshold. Red square indicates a sparse quadrant with BooleanNet statistics s and p. We used a threshold of s > 
3 and p < 0.1 for statistical significance. (A) KLK3 low => ARG2 low. KLK3 low => CD38 low. CD38 high => ARG2 high. (B) Three 
different prostate cancer differentiation states: CD38+ARG2+, CD38-ARG2+, and CD38-ARG2-. (C) ARG2 high => AR high. CD38 high 
=> AR high. (D) A computational model of prostate tissue differentiation.
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and with prostate cancer glands [27]. Heterogeneous loss 
of CD38 in prostate cancer samples compared to normal 
prostate tissues has been observed in a broad survey of 
cell surface (CD) marker expression [28]. The functional 
consequences of low CD38 expression have been explored 
only recently. Low CD38 transcript levels are part of a 
set of 91 transcripts that define a basal/stem cell signature 
in prostate epithelial cells and this signature is enriched 
in aggressive and neuroendocrine-type castrate resistant 
prostate cancers [29]. In a follow-up study, Liu et al. 
demonstrated that luminal cells with low CD38 expression 
are enriched in normal prostate acini adjacent to 
inflammation and these cells have progenitor-like features. 
Isolated cells expressing low levels of CD38 display 
increased expression of inflammatory genes, generate 
significantly more organoids than high CD38 expressing 
Figure 3: Association of ARG2 and CD38 transcript levels with patient outcome. Three prostate cancer differentiation 
states ARG2+CD38+, ARG2+CD38-, and ARG2-CD38- were identified in three independent datasets. (A) Taylor-2010 dataset (n = 140). 
(B) Sboner-2010 dataset (n = 281). (C) Gerald-2004 dataset (n = 78). In all datasets (total n = 499), CD38-ARG2- groups were associated 
with lowest, CD38-ARG2+ groups were associated with moderate, and CD38+ARG2+ groups were associated with highest 10-year 
recurrence-free survival.
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cells, and can generate normal prostate glands and 
carcinomas in an in vivo reconstitution mouse model [30]. 
Chronic inflammation in the prostate has been associated 
prostate carcinogenesis and with decreased AR expression 
in luminal cells, potentially linking inflammation to the 
Boolean relationship we have observed between CD38 
and AR [31]. In addition, the finding that low CD38 
protein expressing cells have a progenitor-like phenotype 
confirms the ability of Boolean analysis to identify genes 
expressed in differentiation pathways in the prostate as we 
have observed in other tissue types [10–12]. 
Less is known about the role of ARG2 in prostate 
cancer. ARG2 expression has been reported to be 
relatively higher in normal and non-malignant prostatic 
tissues compared to prostate cancer tissues [32]. ARG2 
expression is also androgen regulated and has been linked 
to immunosuppressive pathways in human prostate cancer 
[32]. In agreement with this observation, deletion of the 
ARG2 leads to increased tumor size in the TRAMP mouse 
model of prostate cancer [33]. These findings confirm 
the Boolean relationship of ARG2 with AR signaling. 
The finding that the percentage of ARG2 staining was 
prognostic in the Stanford-TMA cohort suggests that 
ARG2 expression could be a marker of differentiation 
and that its loss correlates with more aggressive prostate 
cancer. The lack of validation in the Canary-TMA cohort 
could be due to differences in the scoring procedures used 
that confounded the association of ARG2 with clinical 
behavior. It is possible that re-evaluation and optimization 
of ARG2 scoring, possibly using quantitative imaging 
analysis approaches, will improve performance of this 
biomarker.
Figure 4: ARG2 and CD38 protein levels by IHC and outcome after surgery. ARG2 and CD38 protein expression levels were 
evaluated in two independent cohorts. (A) representative staining of ARG2. (B) Representative staining of CD38. (C) In the Stanford TMA 
dataset, CD38-ARG2- cancer staining shows significantly lower 10-year recurrence-free survival compared to CD38+ARG2+ groups. 
(D) The Canary dataset containing 1105 patients, showed CD38 expressing tumors had significantly higher 10-year recurrence-free 
survival. ARG2 expression in the Canary dataset was not associated with recurrence-free survival.
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Our findings confirm that Boolean analysis 
approaches can be used to identify markers of 
differentiation that have biological and clinical relevance. 
Specifically, we have identified CD38 as a marker 
of differentiation in prostate cancer and confirmed 
that decreased of expression of CD38 transcripts and 
protein by IHC is associated with aggressive prostate 
cancer. These findings agree with recent observations 
demonstrating that CD38 loss correlates with a basal/
progenitor class of luminal cells. As more markers of 
progenitor and stem cells are identifies in the prostate, 
Boolean approaches could yield additional genes relevant 
to prostate differentiation and as clinical biomarkers of 
prognosis. 
METHODS
Gene expression datasets
Publicly available prostate cancer gene expression 
datasets with associated clinical information were 
downloaded from National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus 
website (GEO) and European Bioinformatics Institute 
ArrayExpress [34–36] as described in Supplementary 
Table 1A. A large global prostate cancer microarray 
database (Global-Prostate, n = 891) was created from 
Human U133A (GPL96), Human U133 Plus 2.0 
(GPL570), and Human U133A 2.0 (GPL571) Affymetrix 
platforms as described in Supplementary Table 1B. Gene 
expression values for each Affymetrix platform were 
normalized by robust multichip average (RMA) algorithm 
[37]. Three independent publicly available prostate cancer 
datasets were annotated with recurrence-free survival: 
Gerald-2004 (n = 78, Memorial Sloan-Kettering Cancer 
Center) [23], Taylor-2010 (n = 367, Memorial Sloan-
Kettering Cancer Center) [25], and Sboner-2010 (n = 281, 
Swedish Watchful Waiting cohort) [24].
Boolean analysis of datasets
The expression values of each gene were ordered 
from low to high and a rising step function was computed 
to define a threshold t by the StepMiner algorithm in 
each individual dataset [38]. If the assigned threshold 
for a gene was t, then expression levels above t+0.5 
Table 1: Summary of margin, SVI, ECE, and Gleason by CD38 IHC status
 
CD38 IHC  
All
Moderate/Strong Negative/Weak P-value
N % N %  N %
Margin        
Missing 77 50.99 74 49.01  151 13.67
Positive 159 46.9 180 53.1
0.75
339 30.68
Negative 295 47.97 320 52.03 615 55.66
SVI        
Missing 12 75 4 25  16 1.45
No 495 48.67 522 51.33
0.01
1017 92.04
Yes 24 33.33 48 66.67 72 6.52
ECE        
Missing 4 30.77 9 69.23  13 1.18
No 383 50.66 373 49.34
0.02
756 68.42
Yes 144 42.86 192 57.14 336 30.41
Gleason        
Missing 4 50 4 50  8 0.72
<=6 226 49.34 232 50.66
0.1
458 41.45
3+4 207 50.49 203 49.51 410 37.1
4+3 52 42.98 69 57.02 121 10.95
10-Aug 42 38.89 66 61.11 108 9.77
All 531 48.05 574 51.95  1105 100
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were classified as “high”, and the expression levels 
below t-0.5 were classified as “low”. Expression values 
between t -0.5 and t +0.5 were classified as “intermediate” 
(Supplementary Figure 1A). The previously published 
BooleanNet algorithm was used to determine Boolean 
Implication relationships between genes (Supplementary 
Figure 1B) [39]. Briefly, BooleanNet algorithm searches 
for at least one sparsely populated quadrant in a scatterplot 
between two genes. The “intermediate” expression values 
are ignored by the BooleanNet algorithm. There are six 
Table 2: Univariable cox proportional hazard model of outcomes by clinical and pathological features and CD38 
expression
Endpoint Factor Comparison
Hazard 
ratio
95% 
LCL
95% 
UCL P-value
#Event #Censored
Total 
#patients
RFS CD38 IHC
Moderate/Strong 
vs. Negative/
Weak
0.796 0.668 0.949 0.01 507 598 1105
 Margin Pos. vs. Neg. 2.135 1.767 2.581 <0.0001 431 523 954
 SVI Yes vs. No 0.31 0.235 0.408 <0.0001 496 593 1089
 ECE Yes vs. No 0.527 0.441 0.63 <0.0001 500 592 1092
 Gleason 3+4 vs. <=6 1.324 1.073 1.634 0.01 500 597 1097
  4+3 vs. <=6 2.265 1.733 2.961 <0.0001    
  8–10 vs. <=6 2.345 1.77 3.106 <0.0001    
 Age 1 year increase 1.004 0.991 1.016 0.56 488 515 1003
 Log (Pre-op 
PSA)
1 unit increase 1.91 1.651 2.209 <0.0001 461 525 986
OS CD38 IHC
Moderate/Strong 
vs. Negative/
Weak
0.75 0.434 1.297 0.3 53 1043 1096
 Margin Pos. vs. Neg. 1.517 0.874 2.632 0.14 51 897 948
 SVI Yes vs. No 0.456 0.205 1.011 0.053 52 1029 1081
 ECE Yes vs. No 0.723 0.413 1.266 0.26 51 1032 1083
 Gleason 3+4 vs. <=6 0.816 0.398 1.673 0.58 53 1035 1088
  4+3 vs. <=6 1.517 0.606 3.798 0.37    
  8–10 vs. <=6 3.969 2.024 7.785 0.0001    
 age 1 year increase 1.07 1.026 1.115 0.0017 53 941 994
 Log (Pre-op 
PSA)
1 unit increase 1.65 1.087 2.505 0.02 35 942 977
DSS CD38 IHC
Moderate/Strong 
vs. Negative/
Weak
0.848 0.49 1.466 0.55 52 1048 1100
 Margin Pos. vs. Neg. 2.796 1.429 5.47 0.0027 36 915 951
 SVI Yes vs. No 0.293 0.147 0.584 0.0005 52 1033 1085
 ECE Yes vs. No 0.513 0.294 0.896 0.02 50 1037 1087
 Gleason 3+4 vs. <=6 2.163 1.027 4.552 0.04 51 1041 1092
  4+3 vs. <=6 2.87 1.108 7.434 0.03    
  8-10 vs. <=6 6.513 2.945 14.403 <0.0001    
 age 1 year increase 1.028 0.988 1.07 0.18 51 947 998
 Log (Pre-op 
PSA)
1 unit increase 2.325 1.628 3.321 <0.0001 46 935 981
Hazard ratio higher than 1 means worse prognosis. LCL = lower confidence limit, UCL = upper confidence limit.
RFS: Recurrence Free Survival; OS: Overall Survival; DSS: Disease Specific Survival
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possible scenarios: one of the four quadrants is sparse 
(four independent asymmetric Boolean implications) or 
two diagonally opposite quadrants are sparse (Equivalent 
and Opposite Boolean implications).
Stanford tissue microarray (TMA) resource
All samples used in the construction of the TMA 
were used only for men who signed an IRB-approved 
Informed Consent for use of their tissues samples. A tissue 
arrayer (Beecher Instruments, Sun Prairie, WI) was used 
to construct a prostate cancer tissue microarray (Stanford-
TMA) comprising an independent set of 234 formalin-
fixed, paraffin-embedded primary prostate tumor cases 
selected from radical prostatectomy specimens collected 
at Stanford University, with institutional review board 
approval. Duplicate 0.6 mm tumor cores represented 
each case, and the series was associated with a minimum 
clinical follow-up of 5 years and a median follow-up of 
8 years.
The Canary prostate cancer TMA resource
Tissue blocks and accompanying clinical data 
were collected at each of the participating sites (Stanford 
University, University of California San Francisco, 
University of Washington, University of British Columbia, 
University of Texas Health San Antonio, Eastern Virginia 
Medical School) under a research protocol developed by 
the investigators with IRB approval at each institution. 
The approved protocols included sharing of de-identified 
data and samples and correlation of clinical data with 
biomarker data acquired from the TMAs. A materials 
transfer agreement was developed jointly and approved 
at each site for sharing of clinical data and tissue samples.
Testing of CD38 and ARG2 as clinical biomarkers 
of prognosis was carried out using tissue microarrays 
(TMA) comprised of 4 core samples from over 1300 
randomly selected participants treated for PC with RP at 
six institutions between 1995 and 2004 [8]. The cohort 
includes approximately equal numbers of samples from 
men with biochemically recurrent and non-recurrent PC 
with 5 or more years of follow-up. The TMA (Canary-
TMA) was constructed to assess biomarkers that provide 
prognostic information independent of clinical and 
pathological information. Patient characteristics were 
collected in the clinical data set and included pre-operative 
serum PSA level, pathology stage, Gleason score (GS), 
seminal vesicle invasion (SVI), extracapsular extension 
(ECE), and surgical margin status (positive or negative). 
The primary endpoint was post-surgery recurrence-free 
survival (RFS) from the date of surgery, where the survival 
event was defined as any prostate cancer recurrence 
(biological, clinical/radiological, or use of salvage 
therapy), metastasis, or prostate cancer death. Overall 
survival (OS) and Disease Specific Survival (DSS) were 
secondary endpoints.
Immunohistochemistry (IHC)
Freshly cut 5 micron sections were obtained 
and immunohistochemistry was performed using a 
commercial antibody to CD38 (CD38-290-L-CE, 1:25, 
Leica (Novocastra)) by the Department of Pathology 
Immunodiagnostic Laboratory using standard optimized 
protocols. ARG2 expression was assessed by IHC using 
a commercial antibody (SC20151, 1:50, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA). Cancer cores were 
scored on a 0–3 scale based on staining intensity where 
negative was 0, weak 1, moderate 2 and strong 3 (described 
in Supplementary Figure 2 and 3). In the Stanford cohort, 
ARG2 was scored based on the percentage of positively 
stained tumor cells as described in Supplementary Figure 
4: 0 – 1% positive (score 0), 1 – 33% positive (score 1), 
33 – 66% positive (score 2), 66 – 95% positive (score 
3), and greater than 95% positive (score 4). Because of 
the large number of cases and cores, ARG2 percentage 
scoring was not performed in the Canary TMA cohort. The 
CD38 IHC score used in the analysis was the maximum 
score of all the cores from that patient and the ARG2 IHC 
was the minimum score of all the cores from that patient. 
Strong/moderate scores (score 3 and 2) were considered 
positive, and weak/negative scores (score 1 and 0) were 
considered negative. For the Stanford cohort, ARG2 
percent was used. ARG2 negative (ARG2 –ve) score was 
computed by combining raw ARG2 percentage score 0, 
1, and 2. ARG2 positive (ARG2 +ve) score is computed 
by combining raw ARG2 percentage score 3 and 4. In 
the Stanford cohort, 216 patients had high-quality CD38 
staining and 219 patients had high-quality ARG2 staining 
available for analysis. A combined CD38/ARG2 score was 
generated such that patients were scored “CD38-/ARG2-
ve” if the ARG2 score was 0 or 1 or ARG2 score was 2 
and CD38 score was 0 or 1. Patients were scored “CD38+/
ARG2+ve” if ARG2 score was 3 or 4 or ARG2 score was 
2 and CD38 score was 2 or 3. 
Statistical analysis
Of 1326 patients with clinical data in the Canary 
cohort, 1105 patients had complete high-quality CD38 
staining and 1122 patients had complete high-quality 
ARG2 staining available for analysis with acceptable 
strong uniform TMA staining of the positive controls. 
In this cohort, the scores were analyzed separately as 
prognostic variables since we did not have percentage 
ARG2 staining. Summary statistics of patients’ CD38 
IHC score and other clinical factors (ECE, SVI, margin, 
Oncotarget6560www.impactjournals.com/oncotarget
Gleason score) were provided in frequencies and 
percentages (Table 1). Patient age and pre-op PSA were 
summarized using mean, SD, and range. Fisher’s exact 
test was used to assess correlations between CD38 IHC 
with other clinical factors. Wilcoxon rank sum test was 
used to compare age and pre-operative PSA between 
CD38 IHC groups. Cox proportional hazard models were 
used to assess effect of each factor and multiple factors on 
RFS, OS, and DSS. All tests were two-sided and p-values 
of 0.05 or less were considered statistically significant. 
Statistical analysis was carried out using SAS version 9 
(SAS Institute, Cary, NC) and R version 3.2.3 (2015–12-
10) — “Wooden Christmas-Tree”.
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